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The entry of HIV-1 into target cells is mediated by the viral envelope glycoproteins (Env).
Binding to the CD4 receptor triggers a cascade of conformational changes in distant domains
that move Env from a functionally “closed” State 1 to more “open” conformations, but the
molecular mechanisms underlying allosteric regulation of these transitions are still elusive.
Here, we develop chemical probes that block CD4-induced conformational changes in Env
and use them to identify a potential control switch for Env structural rearrangements. We
identify the gp120 β20–β21 element as a major regulator of Env transitions. Several amino
acid changes in the β20–β21 base lead to open Env conformations, recapitulating the
structural changes induced by CD4 binding. These HIV-1 mutants require less CD4 to infect
cells and are relatively resistant to State 1-preferring broadly neutralizing antibodies. These
data provide insights into the molecular mechanism and vulnerability of HIV-1 entry.
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The entry of human immunodeficiency virus type 1 (HIV-1)into target cells is mediated by the interaction of viralenvelope glycoproteins (Env) with the host CD4 receptor
and CCR5/CXCR4 co-receptor1–7. There are ~10–14 trimeric Env
spikes on the surface of the HIV-1 virion, each composed of three
gp120 exterior glycoproteins associated with three gp41 trans-
membrane glycoproteins. CD4 binding triggers a cascade of
conformational changes in HIV-1 Env that result in the transition
of the Env from the unliganded, metastable, high-energy state to
downstream conformations. These CD4-induced changes involve
gp120 (structural rearrangements in the V1/V2 and V3 loops at
the trimer apex, formation of a bridging sheet, and exposure of
the co-receptor-binding site) and gp41 (formation/exposure of
the heptad repeat 1 (HR1) coiled coil)8–12. Subsequent engage-
ment of the Env-CD4 complex with the co-receptor (CCR5 or
CXCR4) moves the Env down the energy gradient on the entry
pathway, culminating in the formation of a gp41 six-helix bundle
that facilitates the fusion of viral and cellular membranes13–17.
Single-molecule fluorescence resonance energy transfer
(smFRET) studies provided new insights into the energy land-
scape of HIV-1 Env and demonstrated that the HIV-1 Env trimer
samples three distinct conformational states18. Transitions
between these states are spontaneous or induced by CD4 binding.
These states, designated State 1, State 2, and State 3, have been
shown by virological, biochemical, biophysical, and immunologic
studies to correspond to the functionally “closed,” “intermediate,”
and “open” Env conformations, respectively18, 19. The Envs of
primary HIV-1 largely exist in State 1, which is separated by
significant activation barriers from States 2 and 3. CD4 binding
lowers these barriers and stabilizes States 2 and 3, favoring Env
transitions from State 1. Changes in the gp120 V1/V2 region have
been shown to release the constraints that maintain State 1,
allowing increased occupancy of State 219. These mutant viruses
are extremely responsive to CD4 and, compared to the wild-type
virus, are hypersensitive to ligands that recognize downstream
conformations and are resistant to State 1-preferring ligands19.
Whether a result of loss of Env restraints or a consequence of
CD4 binding, all Env transitions from the functionally “closed”
(State 1) conformation to the “open” (State 3) conformation
proceed through State 2 as an obligate intermediate18, 19.
Binding to the CD4 receptor induces allosteric changes in
distant domains of the HIV-1 Env trimer through an incomple-
tely understood mechanism8–12, 18–22. Structural studies mapped
CD4 contacts to a non-continuous set of gp120 residues located
at the tip of the β20–β21 hairpin in the bridging sheet, and at the
“CD4-binding loop” (α3 helix),ℒD loop, and β23/β24 strands on
the outer domain23. CD4 binding induces the rearrangement of
the gp120 V1/V2 and V3 regions at the trimer apex and the
exposure of the gp41 HR1 coiled coil, Env elements that are
distant from the CD4-binding site10–12, 24. How CD4 binding
induces long-range structural rearrangements in HIV-1 Env is
still not well understood. Here, we develop chemical probes and
use them together with a variety of molecular techniques,
including smFRET and genetic analysis, to study the regulation of
HIV-1 transitions upon CD4 binding. We identify the β20–β21
hairpin of gp120 as a site of conformational control in HIV-1
Env, introduce changes in this element that recapitulate the
structural rearrangements induced by CD4, and study interac-
tions between β20–β21 and other gp120 elements. The results
provide a better understanding of the control of discrete HIV-1
Env transitions to downstream conformations on the virus entry
pathway.
Results
Rational design identifies chemical probes. We reasoned that
mapping the conserved binding site of chemical probes that affect
HIV-1 Env rearrangements during virus entry will assist the
identification of key Env residues that regulate conformational
transitions. We developed a panel of structurally related com-
pounds, based on an N,N′-difunctionalized piperazine, which is a
popular building block for synthesis of chemical libraries and a
functional group present in the entry inhibitor BMS-806 (see
Methods and Supplementary Tables 1–3). The set of molecules
was tested for inhibition of a panel of HIV-1 strains that included
transmitted/founder and primary viruses from phylogenetic
clades A, B, C, and D. The half-maximal inhibitory concentration
(IC50) of each compound was determined for each HIV-1 strain
(Supplementary Fig. 1). The data were used to cluster the dif-
ferent HIV-1 strains according to their overall sensitivity, and the
compounds according to their breadth (Fig. 1a). Notably, the
sensitivity profile of the viruses did not segregate with phyloge-
netic clade, but was specified by strain-dependent determinants
(Fig. 1b). Compound 484 exhibited the broadest and most potent
anti-HIV-1-specific activity (Fig. 1c) and was further used to
study Env conformational transitions.
Conformational effects of 484 binding. We used two-color flow
cytometry to measure the effects of 484 binding on HIV-1 Env
conformation (Supplementary Fig. 2). In the absence of soluble
CD4 (sCD4), 484 slightly decreased the binding of the 17b
antibody, which recognizes the gp120 bridging sheet23, 25. In
addition, we observed dose-dependent 484 inhibition of two
CD4-induced structural changes: (1) the movement of the V1/V2
region, monitored by the binding of the quaternary antibody
PG9, and (2) the exposure of the gp41 HR1 coiled coil, detected
with the C34-Ig reagent, which contains the HR2 sequence fused
to an immunoglobulin constant region. Thus, 484 impedes CD4-
induced Env transitions to downstream conformations that are
critical for virus entry10–12, 24, 26. Notably, BMS-806 exhibited a
more limited effect on CD4-induced Env conformational chan-
ges, blocking the exposure of the gp41 HR1 coiled coil but not
gp120 V1/V2 movement24, 26.
We also compared the effects of 484 on HIV-1 Env
conformation with those caused by the binding of a previously
identified small-molecule CD4-mimetic compound (CD4mc),
DMJ-II-12127. The effects of DMJ-II-121 binding on Env
conformational states completely opposed those observed for
484 binding. DMJ-II-121 increased the exposure of both the
gp120 bridging sheet (based upon 17b binding) and the gp41
HR1 coiled coil (based on C34-Ig binding) in a dose-dependent
manner (Supplementary Fig. 2). Thus, DMJ-II-121 binding
promotes Env transitions from State 1 to States 2 and 3,
consistent with its ability to mimic CD4 binding. Conversely, 484
blocks CD4-induced Env transitions from State 1 to downstream
conformations.
Resistance and sensitivity to 484 and DMJ-II-121. Despite
binding to a small region on HIV-1 Env, 484 and DMJ-II-121
modulate large-scale structural rearrangements in the viral spike.
We reasoned that information on the binding sites of 484 and
DMJ-II-121 could implicate specific regions of HIV-1 Env in the
control of transitions between conformational states. We tested a
large panel of HIV-1JR-FL variants with single-residue changes in
Env for their sensitivity to these compounds. Resistance to 484
resulted from changes in the gp120 β20–β21 element, α1 helix,
Phe 43 cavity, and V1/V2 region (Fig. 2a); resistance to DMJ-II-
121 was mostly associated with amino acid changes around the
gp120 Phe 43 cavity, which constitutes the known binding site for
DMJ-II-121 and the other CD4mc27 (Fig. 2b). A cluster of
changes in the V1/V2 region (I154A, N156A, Y177A, and L193A)
resulted in viruses that were extremely sensitive to DMJ-II-121
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but resistant to 484. These changes have been shown to desta-
bilize State 1 and increase Env sampling of downstream con-
formations, indirectly rendering HIV-1 more sensitive to CD4mc
and less sensitive to conformational blockers19, 24. The resistance-
associated changes in gp120 residues Trp 112, Ile 424, Met 426,
and Tyr 435 suggest a potential 484-binding site between the α1
helix and β20–β21 element. Consistent with this interpretation
are the significant increases and decreases in 484 sensitivity
observed for different substitutions of Met 426, with little effect













































































































































0.4 1.5 1 1 5.5 3.2 4 8.6 15.3 4.7
0.7 12.9 10.8 5.2 5.8 14.6 17.1 22.1 27.6 12.8
2.7 2.9 3.6 5.7 6.4 18.2 9.8 21.1 25.5 112
3.8 8.6 40 27.9 4.6 10.8 5.3 18.9 44.4 112
5.4 19.9 16 21.8 13.1 34.5 33.6 52 47.6 74.2
4 3.4 11.7 17.7 48.5 9.8 31.2 21.4 46.8 77
1.4 6.3 16.5 12.7 43.1 17.7 58.6 29 38 112
7.9 38.6 18.9 13.1 97.5 9.4 112 103 43.5 74.6
11.2 22.1 25.9 37.3 40.8 65.5 36.3 112 112 112
22.2 55.7 49.7 49.8 17.6 112 73.7 104 95.8 112
30.7 41.3 48.3 112 62 112 112 112 112 112
37.8 56.3 50 93.4 85 112 112 112 97 112
33.4 112 65.7 112 112 93.8 112 112 112 112
















































































Fig. 1 Chemical probes of HIV-1 Env function. a A panel of chemical probes was developed and tested for inhibition of a diverse set of HIV-1 strains from
different clades. The average IC50 values were calculated from those obtained in two or three independent experiments. The IC50 of each compound for
each virus strain is plotted on a heat map; the compounds are ordered according to the geometric mean IC50 of each compound against the panel of viruses
and the viruses are clustered according to the combination of IC50s of the set of compounds against a specific strain. Transmitted/founder, acute/early,
and primary isolates are shown with purple, light blue, and black letters, respectively. Under the conditions tested, variation of up to two orders of
magnitude in sensitivity to the different compounds was observed across different HIV-1 isolates. b The geometric mean IC50 of all compounds against
each specified HIV-1 strain. c The geometric mean IC50 of each specified compound against the panel of viruses
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the HIV-1BG505 soluble gp140 (sgp140) SOSIP.664 Env were
unsuccessful, but parallel efforts determined the structure of other
conformational blockers, BMS-806 and BMS-626529, in a com-
plex with this Env trimer28. We used the crystal structure of HIV-
1BG505 sgp140 SOSIP.664-BMS-626529 (after removing the
bound BMS-626529) to model the binding of 484. Docking
several newly designed and synthesized 484 analogs (i.e., 484-3–
484-18 in Supplementary Table 5) into the Env trimer structure
led to binding scores that correlated with the IC50s of the com-
pounds, emphasizing the reliability of this analysis and indicating
a binding site close to the β20–β21 element (Fig. 2c, d, Supple-
mentary Table 5, and Supplementary Figs. 3–5). The proposed
binding site was consistent with the ability of 484 to decrease the
binding of the 17b antibody, which contacts β20–β21, as well as
the location of gp120 changes associated with 484 resistance.
Notably, this model suggests that CD4mc and conformational
blockers like 484 bind proximal to and on opposite sides of the
gp120 β20–β21 element, which also contains residues that contact
CD423, 29, 30.
Involvement of gp120 β20–β21 in maintaining Env State 1.
Mapping the binding sites of CD4mc and conformational
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Fig. 2 Genetic analysis and binding sites of chemical probes of HIV-1 Env conformation. a, b Amino acid residues associated with resistance or
hypersensitivity to 484 and the CD4-mimetic compound DMJ-II-121 are shown on structures of the HIV-1BG505 soluble gp140 (sgp140) SOSIP.664
glycoprotein. We used an Env structure without sCD4 (Protein Data Bank (PDB) 4TVP)30 for mapping 484 susceptibility, and a CD4-bound Env
conformation (PDB 5THR)22 for mapping DMJ-II-121 susceptibility. The CD4-bound Env model represents a fit of the sgp140 SOSIP.664 structure to an
8.9-Å-resolution cryo-EM density map; the model lacks the V1/V2 region, which is schematically represented (yellow sphere). In comparison with the
structure of sgp140 SOSIP.664 without sCD4, the density map shows a large CD4-induced movement of the V1/V2 region of gp12022. The color code key
indicates the level of resistance for the specified residues. The ratio of the mutant to wild-type HIV-1JR-FL IC50 values (fold change) for resistant and
hypersensitive HIV-1 mutants is shown in parentheses; the IC50 value of each Env mutant is shown in Supplementary Table 4. Infectivity of the mutant
HIV-1JR-FL viruses was not significantly affected by the amino acid changes except for two changes (I154A and N156A). The expanded image in the lower
panel of a shows a docking pose of the 484 compound in the crystal structure of the HIV-1BG505 soluble gp140 SOSIP.664 component of the complex with
BMS-62652928. The expanded image in the lower panel of b shows the crystal structure of DMJ-II-121 in complex with the HIV-1C1086 gp120 core (PDB ID
4I53).27 c, d The relationship between either the docking scores (c) or docking energy (d) and the antiviral activity of a panel of 484 derivatives was used
to assess the reliability of the docking in a. The dashed line indicates the linear trend between the docking score and IC50 values. The scores and derivatives
analyzed are shown in Supplementary Table 5. As a control, the BMS-626529 compound was docked into the crystal structure (Supplementary Fig. 4). Red
color, non-active compounds (IC50> 112 μM). Rs, Spearman coefficient; PS, Spearman P value; P, t test P value
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suggested that residues within this gp120 element might control
Env structural rearrangements. Substantial repositioning of β20–
β21 after sCD4 binding further supports this hypothesis (Fig. 2a,
b). We therefore used Env ligands that recognize downstream
conformations to evaluate the effect of changes in the gp120
β20–β21 structure on the conformational state of Env. These
ligands included sCD4; the 19b monoclonal antibody (Mab)


















WT 420 421 422 423 424 425 426 428 429 430 431 432 433 434 435
I K Q I I N M Q E V G K A M Y
19b 4.5 7.8 3.7 0.1 0.01 1.8 0.8 0.7
17b 9.6 39.2 65.6
902090 60 27 23 2 16 33 68 59 21 40 15
T20 2.1 0.7 2.1 0.21 2.7 0.27 0.22 0.18 2.9 2 2.1 2.6 1.5 1.77 3
sCD4 19 24.9 2.3 3.3 1.3 29.3 135 154 65.7 20.2 386 19 30.1 15.7 3.0 46
Binding 1.0 0.5 1.3 1.4 1.3 1.0 0.4 0.6 0.5 1.2 0.8 0.6 0.8 1.0 0.4 0.6
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Fig. 3 Involvement of the gp120 β20–β21 element in regulation of HIV-1 Env conformational transitions. a, b Effect of single-residue changes in the
gp120 β20–β21 hairpin on the sensitivity of HIV-1JR-FL to neutralization by the V3-directed 19b antibody a and by sCD4 b. Changes that increased HIV-1
susceptibility to the specified ligand are shown in blue and all others in red. Residues that contact CD4 are indicated with an asterisk. c Phenotypes
associated with gp120 β20-β21 residues. Trp 427 could not be tested due to the low level of replication of the W427A and W427F viruses. d Average IC50
values of inhibition of HIV-1JR-FL with the β20–β21 changes listed in a and b by conformation-sensitive Env ligands. Reported units are μg ml−1 for 19b, 17b,
902090, and 830 A, and nM for sCD4 and T20; sCD4 binding to the cell-surface Env is normalized to the WT Env values. Reported values for sCD4
inhibition were normalized for sCD4 binding. When IC50 values were above the tested concentrations, the highest concentration tested is shown in blue
letters and is underlined. Values that were significantly below or above the ones obtained for WT HIV-1JR-FL are highlighted with blue and red backgrounds,
respectively. e Relationships between the effect of changes in residue 435 on the sensitivity of HIV-1JR-FL to sCD4 and the polarity, contact energy (in RT
units, R= universal gas constant and T= temperature)48, and buriability49 for each amino acid change. f The effect of changes in residue 422 (left) and
residue 435 (right) on the sensitivity of HIV-1JR-FL to the V3-directed 19b antibody. P values were calculated using a one-sample t test (f, left), a
Mann–Whitney test for the difference between the groups (e, left and f, right), or Spearman correlation (e, middle and right). Results shown are the
average of those obtained in two or three independent experiments (see also Supplementary Fig. 7). WT, wild-type
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830A, directed against a V2 β-barrel; 17b, a CD4-induced (CD4i)
MAb; and T-20, an HR2 peptide that targets the gp41 HR1
coiled coil (Supplementary Table 6). Specific changes in the
base of the β20–β21 structure (residues 421–424 and 433–435)
resulted in HIV-1JR-FL hypersensitivity to the ligands recognizing
downstream (State 2 and State 3) Env conformations (Fig. 3).
Of note, the I423A mutant was hypersensitive to multiple
ligands that recognize distinct Env structural elements involved in
conformational transitions: V3, V1/V2, and β20–β21 (in gp120)
and HR1 (in gp41) (Fig. 3a–d). The I423A virus exhibited
increased sensitivity to State 2-/State 3-recognizing ligands, such
as the weakly neutralizing antibody against the CD4-binding
site (F105) and several MPER-directed antibodies (4E10, 7H6,
and 10E8), which have been shown to recognize downstream
(State 2/State 3) Env conformations preferentially19, 24. By con-
trast, the I423A virus was relatively resistant to neutralization
by broadly neutralizing antibodies that have been shown to
bind State 1 Env preferentially (i.e., the PG9 antibody and the
CD4-binding site antibodies VRC01, VRC03, and 3BNC117
(Fig. 4a, b))18, 19, 24, 31–33. These results indicate that, relative to
wild-type HIV-1JR-FL, the I423A virus more frequently samples
States 2 and 3.
Virus sensitivity to sCD4 could be modulated by altering the
buriability of the highly conserved Tyr 435, which does not
contact CD423 (Fig. 3e). The presence of a hydroxyl group at
residue 435 on the background of different isolates may be
important in vivo, as most HIV-1 isolates that contain a
residue other than tyrosine have a serine residue at this
position (Supplementary Fig. 6). Almost all changes in
Tyr 435 and Gln 422 led to increased virus sensitivity
to the 19b anti-V3 loop antibody (Fig. 3f and Supplementary
Fig. 7); in some Env structures (PDB 4TVP), these residues
are close to each other and to the V3 region. Overall, the
β20–β21 gp120 region contacts CD4 and contains residues that
are involved in the maintenance of State 1. Specific alterations of
these residues modulate allosteric changes in the trimer apex
(V1/V2 and V3 regions), the gp41 ectodomain, and the
CCR5-binding site.
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Fig. 4 The effects of the I423A change in different primary HIV-1 strains on Env conformational state and sensitivity to broadly neutralizing antibodies.
a Neutralization of wild-type (WT) (blue) and I423A (red) HIV-1JR-FL by different bNAbs. The calculated IC50s are shown. b Conformation-selective bNAbs
and sCD4 were used to test the sensitivity of the WT (blue) and the I423A variant (red) of HIV-1 strains from clades A, B, C, and D. Reported IC50 units are
nM for sCD4 and μg ml−1 for the bNAbs. The asterisk (*) indicates that sensitivity of the PG9 antibody was tested against the HIV-1JR-FL E168K + N188A
Env (with and without the I423A change); these V2 changes restore the PG9 epitope in the HIV-1JR-FL Env32, 47. c Comparison of the sensitivity of all
isolates from b to ligands that prefer State 1 and State 3. Results shown are the average of those obtained in two or three independent experiments and
error bars represent s.e.m. The double asterisk (**) indicates one-tail P values <0.05
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Conserved effect of the I423A change on Env conformation.
We used broadly reactive Env ligands that preferentially recog-
nize specific Env conformations to test the effects of the I423A
change in different HIV-1 isolates. Virus sensitivity to sCD4
(State 2/3-preferring) and to the PG9 and VRC03 (State 1-pre-
ferring) antibodies was used as a surrogate for Env conforma-
tional transitions19, 32, 33. The I423A mutants from all HIV-1
clades tested were more sensitive to sCD4 inhibition and more
resistant to PG9 and VRC03 inhibition in comparison to the
related wild-type viruses (Fig. 4c). The general effect of the I423A
change in different HIV-1 strains is consistent with the high
degree of conservation of the amino acids that form the β20–β21
element, including Ile 423 (90.5% among 2500 primary HIV-1
isolates). Moreover, substitutions that naturally occur at reside
423 are mostly limited to amino acids that maintain State 1
(Supplementary Fig. 8). These observations support the impor-
tant role of Ile 423 in maintaining a State 1 conformation in
different HIV-1 strains.
β20–β21 changes decrease CD4 requirements for HIV infection.
Since CD4-induced Env transitions to downstream conforma-
tions can be recapitulated by changes in β20–β21 such as I423A,
we measured the CD4 requirement of viruses carrying this change
(Fig. 5a, b). The I423A mutant required significantly less CD4mc
or sCD4 to trigger virus entry than did the wild-type Env. The
I423A mutant also infected cells that express low levels of CD4
more efficiently than the wild-type virus (Fig. 5b). These results
indicate that, compared with the wild-type HIV-1JR-FL, the I423A
mutant needs less CD4 to make the transition into the CD4-
bound conformation.
To examine the conformational states of the I423A mutant
directly, we used smFRET analysis to study the I423A Env in the
presence and absence of a conformational blocker, BMS-626529
(Fig. 5c). This analysis showed that, compared to the wild-type
Env, the I423A mutant exhibited decreased occupancy of State 1
and increased occupancy of State 3. Conformational blockers like
BMS-626529 have been shown to decrease HIV-1 Env transitions
from State 1, leading to increased occupancy of State 118, 19, 24.
The distribution of the I423A conformational states was
minimally affected by BMS-626529 treatment. The relative
increase in the spontaneous sampling of downstream conforma-
tions by the I423A mutant explains the sensitivity of this virus to
Env ligands that preferentially bind these conformations.
Interactions between the gp120 β20–β21 and V1/V2 regions.
We recently reported that Leu 193 in the gp120 V1/V2 region
helps to maintain Env from diverse HIV-1 strains in State 119.
Given the similarities in the HIV-1 phenotypes associated with
changes in the gp120 V1/V2 and β20–β21 regions, we investi-
gated potential functional interactions between these gp120 ele-
ments. The phenotypes of HIV-1JR-FL mutants with alterations in
either Leu 193 or Ile 423 were compared with mutants containing
changes in both residues. Both the L193A and I423A mutants
exhibited dramatic increases in sensitivity to sCD4, the 19b anti-
V3 antibody, and the 902090 anti-V2 antibody, consistent with
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Fig. 5 The effect of the I423A change on CD4 dependence and Env conformation. a Recombinant viruses carrying the wild-type (WT) or I423A HIV-1JR-
FLEnv were incubated with CD4-negative, CCR5-expressing Cf2Th cells in the presence of the CD4-mimetic compound DMJ-II-121 or sCD4 at the indicated
concentrations. The percentage of maximal infection for each virus variant is reported here. The maximal infection levels after DMJ-II-121 addition were
297,656 and 70,626 relative luciferase units for viruses with the WT and I423A Envs, respectively. Error bars represent s.e.m. b Infection of cells with
different levels of CD4. Left, parallel titration of wild-type (WT) or I423A HIV-1JR-FL on affinofile cells that were induced to express low or high levels of
CD4. Right, the effect of different levels of CD4 expression, induced by doxycycline treatment of affinofile cells, on the infectivity of WT or I423A HIV-1JR-
FL. Maximal infection levels were 675,978 and 613,708 relative luciferase units for viruses with the WT and I423A Envs, respectively. c Single-molecule
fluorescence resonance energy transfer (smFRET) probes were placed in the gp120 V1 and V4 loops of WT or I423A HIV-1JR-FL Envs. The FRET trajectories
were compiled into population FRET histograms and fit to the Gaussian distributions associated with each conformational state, according to a hidden
Markov model18. The percentage of the population that occupies each state as well as the number of molecules analyzed is shown and represents the
average of two independent experiments
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downstream conformations (Fig. 6a). The difference in the level
of sensitivity of these two mutants to the 17b CD4i antibody likely
results from the partial disruption of the 17b epitope by the I423A
change34, which was also manifested in the low 17b sensitivity of
the L193A/I423A mutant. The sensitivity of the L193A/I423A
mutant to sCD4, 19b, and 902090 was similar to those of the Env
mutants with the individual residue changes. Thus, the pheno-
typic effects of the L193A and I423A changes on HIV-1JR-FL
sensitivity to sCD4 and anti-V2/V3 antibodies are redundant.
We next examined the phenotypes associated with the I423V
change in the contexts of wild-type HIV-1JR-FL or an L193A
mutant. The change in isoleucine 423 to valine has been
previously reported to contribute to the CD4-independent
phenotype of the laboratory-adapted HIV-1HXBc2, but showed
no effect on HIV-1JR-FL35. Consistent with these results, we found
no significant effect of this change on HIV-1JR-FL sensitivity to
sCD4 or the 17b, 19b, and 902090 antibodies (Fig. 6a). However,
the addition of the I423V change to the L193A mutant virus
significantly enhanced its sensitivity to these different ligands,
which recognize downstream Env conformations. Thus, the effect
of the I423V change on the conformational state of Env is
dependent upon the presence of the L193A change. These
observations suggest a model in which the L193A and I423A
changes release the restraints on State 1, allowing Env to populate
the downstream States 2 and/or 3. On its own, the I423V change
does not appreciably destabilize State 1; however, once State 1 has
been destabilized by the L193A change, the I423V change may
facilitate transitions between downstream states (e.g., between
State 2 and State 3).
The above mutagenesis study indicates functional cooperativity
between two different gp120 residues: Leu 193 in the V1/V2
region and Ile 423 in the β20/β21 element. Of note, Leu 193 and
Ile 423 are in close proximity on some structures of HIV-1 Env








































































































































































































Fig. 6 Interaction between residues in the gp120 β20–β21 element and the V1/V2 region. a The individual and combined effect of changes in Ile 423 and
Leu 193 on the sensitivity of HIV-1 to ligands recognizing downstream conformations. Results shown are averages of those obtained in two or three
independent experiments and error bars represent s.e.m. Indicated P values were calculated using a two-sample t test. b Leu 193 and Ile 423 were mapped
on a structure of HIV-1 Env bound to the PGT151 antibody (PDB ID 5FUU)36. c Analysis of the prevalence of amino acids other than isoleucine at position
423 or leucine at position 193 among 2500 primary HIV-1 strains. Green pie plots show the prevalence in all HIV-1 strains and residue-specific pie plots
(set to the same size as the green plots) show the prevalence of specific amino acids within the HIV-1 subpopulation that carries amino acids other than
isoleucine at position 423 or leucine at position 193. d Possible combinations of different amino acids at Env residues 193 and 423 in primary HIV-1 strains.
The number of isolates with the specified pairing is indicated
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possible mechanism for the cooperative regulation of Env
transitions (Fig. 6b). These observations prompted us to analyze
the covariation of these two residues in different primary HIV-1
strains. Analysis of 2500 env sequences (from the HIV-1 database,
https://www.hiv.lanl.gov/) showed that Leu 193 and Ile 423 are
both highly conserved, with 97.6 and 90.5% identity, respectively,
among different HIV-1 strains. Remarkably, HIV-1 strains that
contain a residue other than isoleucine at position 423 exhibit a
2.5-fold enrichment in substitutions for leucine at position 193.
Similarly, a change in Leu 193 was associated with a 3.1-fold
increase in substitutions for isoleucine at position 423 (Fig. 6c and
Table 1). Analyzing this effect in each of the β20–β21 residues
showed that the degree of co-variation with Leu 193 was greater
for Ile 423 than for any other β20–β21 residue (Table 1). Thus,
optimal Env configurations may require compatible combinations
of residues at these positions. The identification of less prevalent
HIV-1 strains that have Env residues other than leucine (at
position 193) and isoleucine (at position 423) allowed us to assess
the compatible combinations of these residues on the background
of different isolates (Fig. 6d). An isoleucine residue at 193 was
paired with different hydrophobic amino acids at position 423
and this apparent flexibility is consistent with the increased ability
of Envs with Ile 193 to maintain State 1, relative to Envs with Leu
19319. Other substitutions at position 193 were less tolerated and
each matched a specific residue at position 423, indicating that in
diverse HIV-1 strains, there may be subtly different requirements
for maintaining β20–β21–V1/V2 interactions.
Discussion
We developed chemical probes of HIV-1 Env function that block
two CD4-induced conformational changes and used them to map
a control switch for Env structural rearrangements. Compound
484 exhibits broad range activity against diverse HIV-1 strains
from different clades and interferes with Env structural rearran-
gements, making it an attractive probe for mapping conserved
regulatory elements in HIV-1 Env. HIV-1 Env changes that
resulted in resistance to 484 inhibition were of two types. One
set of changes, in the gp120 V1 and V2 variable regions and the
β20–β21 element, resulted in HIV-1 resistance to 484 and
increased sensitivity to a CD4-mimetic compound. This pheno-
type is associated with Env changes that destabilize State 1 and
increase Env transitions from State 1 to downstream
conformations19, 24. Recently, changes in HIV-1 gp41 have been
described that stabilize State 1 and render the virus more sensitive
to inhibition by 484 and more resistant to CD4-mimetic com-
pounds37. Thus, HIV-1 variants with higher occupancy of State 1
often exhibit increased sensitivity to inhibition by conformational
blockers like 484. The second set of gp120 changes that conferred
484 resistance defines a conserved hydrophobic pocket flanking
the gp120 β20–β21 element and the α1 helix. Several changes in
the β20–β21 element dramatically reduced HIV-1 sensitivity to
484 without global effects on virus susceptibility to conformation-
sensitive Env ligands; these results are most consistent with direct
disruption of the 484-binding site. This assertion is further
supported by modeling, which takes advantage of very recent co-
crystal structures of other conformational blockers, BMS-626529
and BMS-80628, and accurately predicts the antiviral potency of
484 analogs. The proposed binding site is consistent with the
484-mediated decrease in the binding of the 17b antibody, which
recognizes the gp120 bridging sheet formed upon CD4
binding23, 25, 34. In the CD4-bound gp120 structure23, the resi-
dues implicated in 484-binding line an internal water-filled
channel, explaining the poor accessibility of the binding site in
State 3 to conformational blockers like 48438.
Mapping the potential 484 binding site allowed us to identify
residues in the gp120 β20–β21 element important for the reg-
ulation of conformational changes of the HIV-1 Env. Alteration
of these key residues in the base of the β20–β21 β-hairpin reca-
pitulated several conformational changes induced by CD4 bind-
ing. For example, alteration of Ile 423 to alanine resulted in a
decreased Env occupancy of State 1 and increased spontaneous
sampling of the CD4-bound state (State 3). The I423A mutant is
resistant to Env ligands that prefer State 1 (conformational
blockers, some bNAbs) and hypersensitive to Env ligands that
prefer downstream conformations (sCD4, CD4-mimetic com-
pounds, and some antibodies). The I423A virus requires fewer
CD4 molecules to infect cells, although it does not become
completely CD4-independent.
The metastable HIV-1 Env trimer is maintained in State 1 by
multiple intersubunit and intramolecular interactions
19, 37, 39, 40, 41. Alteration of key restraining residues destabilizes
State 1 and releases the Env trimer to sample downstream con-
formations. The location of restraining residues identified in this
and a previous study19 suggests a potential mechanism for the
induction of structural rearrangements by the CD4 receptor
(Fig. 7). According to this model, CD4 contacts with the loop
connecting the β20 and β21 strands23 disrupt interactions in the
base of the β20–β21 hairpin that stabilize State 1. The binding of
conformational blockers (484, BMS-806, BMS-626529) in the
adjacent hydrophobic gp120 pocket prevents this destabilizing
disruption. Interestingly, peptides derived from the β19–β20
region form nanofibrils in solution, suggesting that out of the
gp120 context this region can adopt alternative conformations42
(Supplementary Fig. 9). The base of the β20–β21 element is
proximal to the base of the V3 region, which, along with V1/V2,
forms the Env trimer apex in all available structures20–22, 30, 36. In
some Env structures, Leu 193 constitutes part of the hydrophobic
Table 1 Frequency of non-consensus amino acids in each of the β20–β21 residues among 2500 primary HIV-1 strains (All) and
among those HIV-1 strains that contain a residue other than leucine at position 193 (L193x)
Residue All (%) L193x (%) Enrichmenta Residue All (%) L193x (%) Enrichment
I420x 1 2 2 E429x 55 39 0.7
K421x 8 6 0.75 V430x 10 12 1.2
Q422x 1 2 2 G431x 1 2 2
I423xb 9.5 29 3.1 K432x 61 43 0.7
I424x 25 33 1.3 A433x 2 2 1
N425x 9 14 1.6 M434x 12 6 0.5
M426x 16 27 1.7 Y435x 1 0 0
W427x 1 0 0
Q428x 2 2 1 Average 1.2
aEnrichment, ratio of the frequency among non-leucine 193 HIV-1 strains to the frequency among all HIV-1 strains. The values associated with the maximal enrichment are indicated in bold.
bP value< 0.00001 in a two-tailed t test for the difference between the enrichment of I423x and other residues
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core of a V2 β-barrel and is proximal to Ile 423 in the β20–β21
hairpin30, 36, 43, 44. These observations suggest a possible
mechanism for conformational regulation of Env transitions by
CD4. CD4-induced changes in the β20–β21 base may destabilize
the hydrophobic core that contains Leu 193, a restraining residue
in the V2 region, and lead to opening the trimer apex. Notably,
the β20–β21 element is the only single gp120 component that
contacts CD4, is proximal to the V3 and V1/V2 loops, and forms
part of the co-receptor-binding site. This may allow β20–β21 to
coordinate CD4 binding with transducing a signal for structural
rearrangements to distant regions.
Our study provides insights into the allosteric regulation of
HIV-1 Env conformational changes by CD4. These insights will
assist the design of inhibitors and the stabilization of specific
Env conformations for use as immunogens and in structural
studies.
Methods
Cells. Cf2Th and 293T were from the American Type Culture Collection. Stocks
were tested for mycoplasma using the MycoAlert detection assay (Lonza).
Identification of new chemical probes. We virtually screened a chemical database
(Enamine) and identified 20 compounds with diverse chemical groups connected
by the selected diketo-piperazine scaffold. These molecules were tested for virus
inhibition and three compounds specifically inhibited HIV-1 entry. The most
potent compound, 118, was used as a scaffold for sequential screening in two cycles
of selection. Follow-up derivatives were subsequently tested for specific HIV-1
inhibition (Supplementary Tables 1–3). The iterative process resulted in a panel of
chemical probes with diverse properties and virus-inhibitory potency.
Compounds. Most compounds were purchased from Enamine. A few compounds
were synthesized, using the synthetic procedures detailed in the Chemical synthesis
section of the Supplementary Methods. All compounds were >90% pure.
Site-directed mutagenesis. Mutations were introduced into the plasmids
expressing full-length HIV-1YU2 or HIV-1JR-FL Envs with the QuikChange II site-
directed mutagenesis protocol or the QuikChange multi site-directed mutagenesis
kit (Stratagene). We confirmed the existence of the mutations by DNA sequencing.
Residues are numbered based on alignments with the HXBc2 prototypic sequence,
according to convention.
Virus production. The 293T cells were co-transfected with an HIV-1 Env-
expressing plasmid, pHIVec2.luc plasmid, and psPAX2 plasmid (cat# 11348, NIH
AIDS Research and Reference Reagent Program) at a ratio of 1:6:3 using Effectene
(Qiagen). The supernatant was collected after 48 h, buffered with 50 mM HEPES
(final concentration) and centrifuged for 5 min at 2000 r.p.m. and 4 °C. The virus-
containing supernatant was used directly or frozen at −80 °C. The amount of p24 in
the supernatant was measured using an HIV-1 p24 antigen capture assay (cat#
5421, Advanced BioScience Laboratories).
Viral infection assay. The viral infection assay was done as previously described24.
Briefly, each test compound was serially diluted in a 96-well B&W isoplate (Per-
kinElmer) using HP D300 Digital Dispenser. DMSO was used as a control and the
final volume of either diluted compound or DMSO was 450 nl. Supernatant (15 ng
p24 Gag) containing viruses pseudotyped with a specific Env was added to each
well and incubated briefly at room temperature. For poorly infectious viruses, the
maximum volume within the assay limit was used. Cf2Th-CD4/CCR5 cells
(derived from Cf2Th cells) were detached using the StemProAccutase Cell Dis-
sociation Reagent (Invitrogen, cat# A11105-01), washed once, and 50 µl of 1 × 105
cells per ml was added to each well. Following a 48-h incubation, the medium was
aspirated and cells were lysed with 30 µl of Passive Lysis Buffer (Promega,
cat#E1941). Activity of the firefly luciferase, which served as a reporter protein in


























Fig. 7 Model of HIV-1 Env conformational regulation. a Changes in the β20–β21 conformation upon CD4 binding. Left, surface representation showing the
location of the β20–β21 element in one gp120 subunit on the HIV-1 Env structure; the ribbon structure of β20–β21 is depicted to the right of the Env surface.
Both representations are derived from the crystal structure of the HIV-1BG505 sgp140 SOSIP.664 glycoprotein (PDB ID 4TVP)30. Right, surface
representation from the cryo-EM structure of HIV-1BG505 sgp140 SOSIP.664 bound to sCD4 (PDB 5THR; the V1/V2 region is shown schematically as a
yellow sphere). The β20–β21 elements from four crystal structures of gp120 from different HIV-1 clades bound to sCD4 or the DMJ-II-121 CD4-mimetic
compound (PDB IDs 4I53, 4I54, 1GC1, and 1RZK) are aligned. A possible trajectory between the upstream state and the CD4-bound state was generated
with the program Chimera50. b Effects of CD4 binding on Env conformation. CD4 contacts the gp120 β20–β21 element, altering the conformation of the
β20–β21 base. Both CD4 binding and changes in restraining residues allow Env to make the transition from State 1 to downstream conformations. Examples
are shown of changes in restraining gp120 residues that affect particular Env transitions
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Technologies, Tennessee, USA) as previously described45. In some experiments, the
compounds (in DMSO) or antibodies (in DMEM medium) were added manually.
All inhibition curves were fitted to the four-parameter logistic equation; IC50 values
and the associated s.e. are reported46.
Flow cytometry. Plasmids expressing wild-type HIV-1JR-FLEnvΔCT or the double-
mutant HIV-1JR-FLEnvΔCT E168K/N188A, which allows recognition by some
quaternary V1/V2 antibodies32, 47, were used for the flow cytometric studies.
Plasmids were transfected using the Effectene transfection reagent (Qiagen) into
293T cells, according to the manufacturer’s instructions. Cells were detached after
48–72 h with 5 mM EDTA/PBS, and about 0.5–1 million cells were briefly incu-
bated with various concentrations of a test compound and then with or without the
indicated concentrations of sCD4. C34-Ig (at a final concentration of 20 μg ml−1)
or a specified antibody (at a final concentration of 1 μg ml−1) was added to the cells.
Following a 30-min incubation, cells were washed twice and incubated with
allophycocyanin-conjugated F(ab′)2 fragment donkey anti-human IgG antibody
(1:100 dilution; catalog no. 709-136-149; Jackson ImmunoResearch Laboratories)
and fluorescein isothiocyanate-conjugated anti-CD4 antibody (1:33 dilution; cat-
alog no. 11-0048-42; E-biosciences) for 15 min. Cells were washed twice and
analyzed with a BD FACSCanto II flow cytometer (BD Biosciences).
Molecular modeling. Target and ligand preparation: The X-ray co-crystal struc-
ture of the BMS-626529 complex with the HIV-1BG505 soluble gp140 SOSIP.664
Env trimer28 was prepared for docking by the Protein Preparation Wizard software
of the Schrödinger 2016-4 suite. This included adding H atoms, assigning bond
orders, filling in missing side chains, and checking amino acid protonation states at
physiological pH using PROPKA and the co-crystallized ligand ionization state at
the same pH using EPIK. Compounds were designed with Maestro 11 and pre-
treated using LigPrep (Schrödinger 2016-4 suite). Their ionization state at phy-
siological pH was analyzed using EPIK and their tautomers were generated.
Docking: Rigid receptor docking was performed using Glide 7.2 (Schrödinger
2016-4 suite). The grid was built on the pretreated target protein and centered on
the co-crystallized BMS-626529, with an inner box size of 10 × 10 × 10 Å and outer
box size of 30 × 30 × 30 Å. Pretreated compounds were docked using the standard
precision (SP) scoring function with the number of poses that undergo post-
docking energy minimization set to 50.
Rescoring: Docking results were rescored by computing the protein–ligand
interaction energy using the Molecular Mechanics/Generalized Born Surface Area
(MM-GBSA) method on a 10 ns molecular dynamics (MD) simulation in water as
explicit solvent by means of NAMD 2.10 and the CHARMM26 force field. The MD
simulation was validated on the BMS-626529/sgp140 SOSIP.664 co-crystal
coordinates28.
Statistical analysis. Statistical parametric analyses were performed by unpaired
Student’s t tests. Statistical nonparametric analyses were done by Spearman rank
correlation and Mann–Whitney tests. We used the nonparametric Levene test to
compare the variance within the different groups that were tested by the
Mann–Whitney test; no significant difference was found between the variance of
the polar and non-polar groups in Fig. 3e (P value >0.05) and a significant dif-
ference was found between the variance of the aromatic and non-aromatic groups
in Fig. 3f (P value <0.05). Summary of the data statistics is included for each
analysis in the relevant figure legend.
Sequence analysis of HIV-1 isolates. The online tool on the HIV-1 database
website (https://www.hiv.lanl.gov/) was used to retrieve the DNA codon at specific
positions in the HIV-1 genome. The data were exported to an Excel worksheet and
the frequency of the translated amino acid was compared among all HIV-1 strains.
The complete Env sequences of HIV-1 strains with amino acids other than leucine
at position 193 were retrieved, exported, and aligned using Clustal omega (http://
www.ebi.ac.uk/Tools/msa/clustalo/). The amino acids around Env position 193 and
the residues comprising the complete β20–β21 element were compared among
HIV-1 strains (Supplementary Table 7).
Data availability. Relevant data are available from the corresponding authors
upon reasonable request.
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